Logo image of SRI

STONERIDGE INC (SRI) Stock Fundamental Analysis

NYSE:SRI - US86183P1021 - Common Stock

8.4 USD
-0.2 (-2.33%)
Last: 8/28/2025, 7:41:59 PM
8.78 USD
+0.38 (+4.52%)
After Hours: 8/28/2025, 7:41:59 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SRI. SRI was compared to 80 industry peers in the Automobile Components industry. The financial health of SRI is average, but there are quite some concerns on its profitability. SRI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year SRI has reported negative net income.
SRI had a positive operating cash flow in the past year.
In the past 5 years SRI reported 4 times negative net income.
SRI had a positive operating cash flow in 4 of the past 5 years.
SRI Yearly Net Income VS EBIT VS OCF VS FCFSRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

SRI has a worse Return On Assets (-4.65%) than 82.50% of its industry peers.
SRI's Return On Equity of -11.42% is on the low side compared to the rest of the industry. SRI is outperformed by 77.50% of its industry peers.
Industry RankSector Rank
ROA -4.65%
ROE -11.42%
ROIC N/A
ROA(3y)-1.86%
ROA(5y)-1.27%
ROE(3y)-4.51%
ROE(5y)-3.02%
ROIC(3y)N/A
ROIC(5y)N/A
SRI Yearly ROA, ROE, ROICSRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

In the last couple of years the Operating Margin of SRI has declined.
Looking at the Gross Margin, with a value of 21.00%, SRI is doing worse than 68.75% of the companies in the same industry.
SRI's Gross Margin has declined in the last couple of years.
SRI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21%
OM growth 3YN/A
OM growth 5Y-44.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5Y-3.99%
SRI Yearly Profit, Operating, Gross MarginsSRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

4

2. Health

2.1 Basic Checks

SRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SRI has more shares outstanding
SRI has a worse debt/assets ratio than last year.
SRI Yearly Shares OutstandingSRI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
SRI Yearly Total Debt VS Total AssetsSRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 2.48 indicates that SRI is not a great score, but indicates only limited risk for bankruptcy at the moment.
SRI has a Altman-Z score (2.48) which is comparable to the rest of the industry.
SRI has a debt to FCF ratio of 5.33. This is a neutral value as SRI would need 5.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.33, SRI is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
A Debt/Equity ratio of 0.63 indicates that SRI is somewhat dependend on debt financing.
The Debt to Equity ratio of SRI (0.63) is worse than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 5.33
Altman-Z 2.48
ROIC/WACCN/A
WACC10.16%
SRI Yearly LT Debt VS Equity VS FCFSRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

SRI has a Current Ratio of 2.14. This indicates that SRI is financially healthy and has no problem in meeting its short term obligations.
SRI's Current ratio of 2.14 is fine compared to the rest of the industry. SRI outperforms 77.50% of its industry peers.
SRI has a Quick Ratio of 1.35. This is a normal value and indicates that SRI is financially healthy and should not expect problems in meeting its short term obligations.
SRI has a better Quick ratio (1.35) than 76.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.35
SRI Yearly Current Assets VS Current LiabilitesSRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

3

3. Growth

3.1 Past

The earnings per share for SRI have decreased strongly by -764.29% in the last year.
Looking at the last year, SRI shows a decrease in Revenue. The Revenue has decreased by -6.99% in the last year.
SRI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.71% yearly.
EPS 1Y (TTM)-764.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
Revenue 1Y (TTM)-6.99%
Revenue growth 3Y5.64%
Revenue growth 5Y1.71%
Sales Q2Q%-3.84%

3.2 Future

SRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.96% yearly.
The Revenue is expected to grow by 1.18% on average over the next years.
EPS Next Y9.74%
EPS Next 2Y59.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-4.93%
Revenue Next 2Y1.18%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRI Yearly Revenue VS EstimatesSRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M
SRI Yearly EPS VS EstimatesSRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1 1.5

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 31.99 indicates a quite expensive valuation of SRI.
77.50% of the companies in the same industry are cheaper than SRI, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SRI to the average of the S&P500 Index (22.78), we can say SRI is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 31.99
SRI Price Earnings VS Forward Price EarningsSRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

66.25% of the companies in the same industry are cheaper than SRI, based on the Enterprise Value to EBITDA ratio.
93.75% of the companies in the same industry are more expensive than SRI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.63
EV/EBITDA 12.66
SRI Per share dataSRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRI's earnings are expected to grow with 59.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.96%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for SRI!.
Industry RankSector Rank
Dividend Yield N/A

STONERIDGE INC

NYSE:SRI (8/28/2025, 7:41:59 PM)

After market: 8.78 +0.38 (+4.52%)

8.4

-0.2 (-2.33%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners101.03%
Inst Owner Change-4.88%
Ins Owners2.28%
Ins Owner Change9.24%
Market Cap235.28M
Analysts86.67
Price Target14.28 (70%)
Short Float %1.53%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-111.49%
Min EPS beat(2)-175.03%
Max EPS beat(2)-47.95%
EPS beat(4)0
Avg EPS beat(4)-241.39%
Min EPS beat(4)-397.03%
Max EPS beat(4)-47.95%
EPS beat(8)3
Avg EPS beat(8)4.55%
EPS beat(12)6
Avg EPS beat(12)18.24%
EPS beat(16)8
Avg EPS beat(16)13.57%
Revenue beat(2)2
Avg Revenue beat(2)2.36%
Min Revenue beat(2)1.8%
Max Revenue beat(2)2.92%
Revenue beat(4)2
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-7.81%
Max Revenue beat(4)2.92%
Revenue beat(8)3
Avg Revenue beat(8)-1.01%
Revenue beat(12)7
Avg Revenue beat(12)1.69%
Revenue beat(16)10
Avg Revenue beat(16)3.27%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)-31.25%
EPS NY rev (3m)-31.25%
Revenue NQ rev (1m)-0.71%
Revenue NQ rev (3m)-12.46%
Revenue NY rev (1m)-1.25%
Revenue NY rev (3m)-1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 31.99
P/S 0.27
P/FCF 7.63
P/OCF 4.56
P/B 0.9
P/tB 1.3
EV/EBITDA 12.66
EPS(TTM)-0.93
EYN/A
EPS(NY)0.26
Fwd EY3.13%
FCF(TTM)1.1
FCFY13.11%
OCF(TTM)1.84
OCFY21.92%
SpS31.34
BVpS9.3
TBVpS6.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.65%
ROE -11.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21%
FCFM 3.51%
ROA(3y)-1.86%
ROA(5y)-1.27%
ROE(3y)-4.51%
ROE(5y)-3.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.54%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-44.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5Y-3.99%
F-Score4
Asset Turnover1.37
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 5.33
Debt/EBITDA 5.86
Cap/Depr 63.18%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion 183.72%
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 1.35
Altman-Z 2.48
F-Score4
WACC10.16%
ROIC/WACCN/A
Cap/Depr(3y)90.27%
Cap/Depr(5y)89.37%
Cap/Sales(3y)3.38%
Cap/Sales(5y)3.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-764.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
EPS Next Y9.74%
EPS Next 2Y59.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.99%
Revenue growth 3Y5.64%
Revenue growth 5Y1.71%
Sales Q2Q%-3.84%
Revenue Next Year-4.93%
Revenue Next 2Y1.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.28%
EBIT growth 3YN/A
EBIT growth 5Y-43.57%
EBIT Next Year178.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y308.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.7%
OCF growth 3YN/A
OCF growth 5Y14.27%